Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 6115

1.

Seroprevalence of transfusion-transmissible infectious agents among volunteer blood donors between 2006 and 2012 in Zhejiang, China.

Zheng X, Ding W, Li G, Wu Y, Wu D, Zhu H, He J, Wang B, Zhao L, Zhu F, Lv H.

Blood Transfus. 2015 Jun 9:1-10. doi: 10.2450/2015.0271-14. [Epub ahead of print]

2.

4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus.

Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D, Venzon DJ, Amano M, Kuwata N, Aoki M, Delino NS, Hayashi S, Takahashi S, Sukenaga Y, Haraguchi K, Sarafianos SG, Maeda K, Mitsuya H.

Hepatology. 2015 Jun 29. doi: 10.1002/hep.27962. [Epub ahead of print]

PMID:
26122273
3.

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group.

Clin Infect Dis. 2015 May 14. pii: civ381. [Epub ahead of print]

PMID:
25977266
4.

A 4-drug combination (Viekira Pak) for hepatitis C.

[No authors listed]

JAMA. 2015 May 12;313(18):1857-8. doi: 10.1001/jama.2015.4562. No abstract available.

PMID:
25965236
5.

King of the pills.

Cohen J.

Science. 2015 May 8;348(6235):622-5. doi: 10.1126/science.348.6235.622. No abstract available.

PMID:
25953989
6.

Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy.

Soria A, Limonta S, Leone S, Muscatello A, Squillace N, Bandera A, Gori A.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):e37-40. doi: 10.1097/QAI.0000000000000541. No abstract available.

PMID:
25942467
8.

Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.

Fagone P, Mangano K, Quattrocchi C, Cavalli E, Mammana S, Lombardo GA, Pennisi V, Zocca MB, He M, Al-Abed Y, Nicoletti F.

Basic Clin Pharmacol Toxicol. 2015 Apr 23. doi: 10.1111/bcpt.12414. [Epub ahead of print]

PMID:
25903922
9.

Head-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study.

Schmidt M, Jimenez A, Mühlbacher A, Oota S, Blanco L, Sakuldamrongpanich T, Schennach H, Seifried E.

Vox Sang. 2015 Aug;109(2):114-21. doi: 10.1111/vox.12259. Epub 2015 Apr 20.

PMID:
25899479
10.

Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.

Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, Zhang J.

Medicine (Baltimore). 2015 Apr;94(15):e646. doi: 10.1097/MD.0000000000000646.

PMID:
25881837
11.

[Postexposure prophylaxis in daily clinical practice].

Küpper MF, Stellbrink HJ, Kern WV, Müller MC.

Dtsch Med Wochenschr. 2015 Apr;140(7):485-8. doi: 10.1055/s-0041-101188. Epub 2015 Mar 31. German.

PMID:
25826030
12.
13.

Treatment to prevent hepatitis B virus reactivation in patients with lymphoma receiving chemotherapy--reply.

Lin T, Huang H, Li X.

JAMA. 2015 Mar 24-31;313(12):1270. doi: 10.1001/jama.2015.1444. No abstract available.

PMID:
25803356
14.

Treatment to prevent hepatitis B virus reactivation in patients with lymphoma receiving chemotherapy.

Baang J.

JAMA. 2015 Mar 24-31;313(12):1269-70. doi: 10.1001/jama.2015.1438. No abstract available.

PMID:
25803354
15.

Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients.

Biçer KÇ, Ari A, Genç VE, Özsu Caymaz S, Avci M, Bal F.

Turk J Med Sci. 2015;45(1):99-104.

PMID:
25790537
16.

Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.

Laohapand C, Arromdee E, Tanwandee T.

Hepatol Int. 2015 Apr;9(2):202-8. doi: 10.1007/s12072-014-9597-6. Epub 2015 Jan 15.

PMID:
25788188
17.

Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.

Milazzo L, Cattaneo D, Calvi E, Gervasoni C, Mazzali C, Ronzi P, Peri AM, Ridolfo AL, D'Avolio A, Antinori S.

Int J Antimicrob Agents. 2015 May;45(5):545-9. doi: 10.1016/j.ijantimicag.2014.12.035. Epub 2015 Feb 21.

PMID:
25769784
18.

Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings.

Stabinski L, OʼConnor S, Barnhart M, Kahn RJ, Hamm TE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S274-85. doi: 10.1097/QAI.0000000000000496. Review.

PMID:
25768867
19.

Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Puri P, Anand AC, Saraswat VA, Acharya SK, Sarin SK, Dhiman RK, Aggarwal R, Singh SP, Amarapurkar D, Arora A, Chhabra M, Chetri K, Choudhuri G, Dixit VK, Duseja A, Jain AK, Kapoor D, Kar P, Koshy A, Kumar A, Madan K, Misra SP, Prasad MV, Nagral A, Puri AS, Jeyamani R, Saigal S, Shah S, Sharma PK, Sood A, Thareja S, Wadhawan M.

J Clin Exp Hepatol. 2014 Jun;4(2):117-40. doi: 10.1016/j.jceh.2014.06.001. Epub 2014 Jun 24. Review.

20.

Corticoid therapy for overlapping syndromes in an HIV-positive patient.

Kaku Y, Kodama S, Higuchi M, Nakamura A, Nakamura M, Kaieda T, Takahama S, Minami R, Miyamura T, Suematsu E, Yamamoto M.

Intern Med. 2015;54(2):223-30. doi: 10.2169/internalmedicine.54.3094. Epub 2015 Jan 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk